Ann: Imugene onCARlytics with Estrella ARTEMIS T Cells SITC, page-52

Yes, their new website mentions IMU's CF33-CD19t Oncolytic Virus in many places and it appears to be a key component of their value prop for listing their new company in the near future.

I particularly like these statements:

"Estrella’s President and CEO, Cheng Liu, PhD and the current management team will continue to lead the Combined Company. Dr. Liu will also continue in his role as President and CEO of Eureka."

“Estrella is committed to making a meaningful difference in areas of unmet medical needs by continue advancing our pipeline programs into the clinics. The team is confident that fueled by ARTEMIS® technologies, EB103 and EB104 have the potential to address blood cancers while mitigating safety concerns. Meanwhile, we plan to extend the use of our CD19 ARTEMIS®️ T-cell therapy into diverse solid tumors by combining with Imugene’s CF33-CD19t in the novel “Mark and Kill” approach,” said Dr. Liu, President and CEO of Estrella. “We are delighted to have found such a stellar group of partners and investors as we take the next step in our growth trajectory as a public company.”

Weiguan Yang, Co-CEO of TradeUP, commented: “We are truly excited about the merger with Estrella. Estrella represents a rare opportunity to further advance T-cell therapies in minimizing life-threatening side effects such as Cytokine Release Syndrome (“CRS”) and has the potential to address blood cancers while mitigating safety concerns. The collaboration with Imugene is expected to tackle the major challenge for current T-cell therapies in solid tumor treatment. We believe this business combination will provide Estrella or the Combined Company the financial resources to continue developing its lead drug candidate and bring its novel therapies to fruition.”

I think the public listing of Estrella in the USA market will provide IMU was an excellent marketing platform. Chen Lie seems happy with the recent results and is keen to progress further across several fronts.

As a refresh, here are a few slide images from the IMU presentation pack dated 01/11/2021 when the Eureka collaboration was announced.










It will be good to have an USA listed company in our court and promoting the safety & efficacy of IMU's CF33-CD19t Oncolytic Virus.

GLTAHs